STOCK TITAN
  1. Home
  2. News
  3. PRAX

Praxis Precision Medicines Inc - PRAX STOCK NEWS

Welcome to our dedicated news page for Praxis Precision Medicines (Ticker: PRAX), a resource for investors and traders seeking the latest updates and insights on Praxis Precision Medicines.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Praxis Precision Medicines's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Praxis Precision Medicines's position in the market.

News
Praxis Precision Medicines, Inc. Announces Pricing of $150.0 Million Public Offering
Rhea-AI Summary
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) announced the pricing of its underwritten public offering of 3,168,275 shares of its common stock at a public offering price per share of $35.50, with expected gross proceeds of approximately $150.0 million. The offering also includes pre-funded warrants to purchase up to an aggregate of 1,056,725 shares of common stock at a purchase price of $35.4999 per pre-funded warrant. The underwriters have been granted a 30-day option to purchase up to 633,750 additional shares of common stock at the public offering price.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.66%
Tags
offering
-
News
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
Rhea-AI Summary
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) announced a proposed public offering of its common stock and prefunded warrants to purchase shares of common stock. The offering, subject to market conditions, is being made pursuant to a shelf registration statement filed with the SEC. The final terms will be disclosed in a final prospectus supplement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.66%
Tags
offering
-
News
Praxis Precision Medicines Provides Update on Advancing Clinical Stage Portfolio
Rhea-AI Summary
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) provided an update on its portfolio and planned key milestones in 2024, including positive preliminary analysis of the PRAX-628 study in epilepsy patients with Photo-Paroxysmal Response (PPR), on-track enrollment for ulixacaltamide Phase 3 Studies, and a recently announced licensing partnership with Tenacia Biotechnology to develop and commercialize ulixacaltamide in Greater China with total consideration over $275 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
24.85%
Tags
none
News
Praxis Precision Medicines Announces Licensing and Collaboration Agreement with Tenacia Biotechnology for Ulixacaltamide in Greater China
Rhea-AI Summary
Praxis Precision Medicines, Inc. (PRAX) announces a collaboration and license agreement with Tenacia Biotechnology (Shanghai) Company, Ltd. for the development and commercialization of ulixacaltamide for the treatment of essential tremor in Greater China. Praxis will receive upfront proceeds of $15 million and is eligible to receive up to $264 million in milestone payments as well as tiered royalties.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.12%
Tags
none
-
News
Praxis Precision Medicines to Showcase Largest Pipeline of Precision Epilepsy Programs and Breadth of Commitment to Epilepsy Treatments at Upcoming Meetings
Rhea-AI Summary
Praxis Precision Medicines (PRAX) will present new patient data and updates on clinical progress for its epilepsy programs at upcoming meetings in Orlando, Florida. The company aims to discuss its potential impact on patients and families with the epilepsy community.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.09%
Tags
none
-
News
Praxis Precision Medicines to Present at the Piper Sandler 35th Annual Healthcare Conference
Rhea-AI Summary
Praxis Precision Medicines, Inc. (PRAX) will participate in a fireside discussion at the Piper Sandler Healthcare Conference on November 28, 2023 at 10:00am. The event will be available via live webcast through the company’s website. A replay of the webcast will be available for 90 days following the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.61%
Tags
conferences
News
Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsies
Rhea-AI Summary
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) Receives EMA's PRIME Designation for Elsunersen (PRAX-222) for SCN2A Gain of Function Developmental and Epileptic Encephalopathy (DEE)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.93%
Tags
none
-
News
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
Praxis Precision Medicines, Inc. reported a corporate update and financial results for the third quarter 2023, with a cash balance of $101.1 million as of September 30, 2023, supporting runway into Q1 2025. The company initiated Essential3, the Phase 3 program for ulixacaltamide, and completed the final dosing for Part 1 of the EMBRAVE study for the treatment of pediatric patients with early-onset SCN2A-DEE. Praxis also expects topline results from the PRAX-628 Phase 2a proof-of-concept study in the fourth quarter of 2023 and from the PRAX-562 Phase 2 EMBOLD study in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.49%
Tags
earnings
-
News
Praxis Precision Medicines to Present at Truist Securities BioPharma Symposium
Rhea-AI Summary
Praxis Precision Medicines, Inc. announced that management will participate in a panel discussion at the Truist Securities BioPharma Symposium on November 8, 2023. The event will be available via live webcast on the company's website, with a replay available for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.43%
Tags
conferences
News
Praxis Precision Medicines Provides Portfolio Update at 2023 R&D Day
Rhea-AI Summary
Positive results from preliminary analysis of PRAX-222 Part 1 showed 44% median reduction in seizures after three doses for SCN2A-gain-of-function pediatric patients Phase 3 (Essential3) program for ulixacaltamide initiating this quarter with mADL11 as primary endpoint; nearly 600 patients have already expressed interest in participating.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.34%
Tags
none
Stock PRAX logo
Praxis Precision Medicines Inc

Nasdaq:PRAX

PRAX Rankings

#2504 Ranked by Market Cap
#4647 Ranked by Stock Gains
N/A Ranked by Dividends

PRAX Stock Data

942.57M
13.21M
0.17%
48.92%
3.26%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Boston

About PRAX

praxis precision medicines, inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. its lead product candidates include prax-114, an extrasynaptic-preferring gabaa receptor positive allosteric modulator that is in phase iia clinical trial for the treatment of major depressive disorder and perimenopausal depression; and prax-944, a selective small molecule inhibitor of t-type calcium channels, which is in phase iia clinical trial for the treatment of essential tremor. the company is also developing prax-562, a persistent sodium current blocker that is in phase i clinical trial to treat severe pediatric epilepsy and adult cephalgia; prax-222, an antisense oligonucleotide for patients with gain-of-function (gof) scn2a epilepsy; and kcnt1 program for the treatment of kcnt1 gof epilepsy. it has a cooperation and license agreement with rogcon inc.; a license agreement purdue neuroscience company; and a res